TABLE 1.
Patient demographics, clinical characteristics, and underlying conditions at baseline in patients receiving recommended doses of LMWH
| Enoxaparin | Dalteparin or tinzaparin | |
|---|---|---|
| Patients, N | 3526 | 925 |
| Demographics | ||
| Male sex, n (%) | 1670 (47) | 448 (48) |
| Age (mean years ± SD) | 68 ± 13 | 67 ± 13 |
| Body weight (mean kg ±SD) | 73 ± 14 | 74 ± 14 |
| Race/ethnicity a , n (%) | ||
| White | 1315 (37) | 292 (32) |
| Latino | 39 (1.1) | 5 (0.5) |
| Asian | 19 (0.5) | 3 (0.3) |
| Arab | 4 (0.1) | 4 (0.4) |
| Mixed/other | 15 (0.4) | 6 (0.6) |
| Not provided | 2134 (61) | 615 (66) |
| Initial VTE presentation, n (%) | ||
| PE | 2058 (58) | 411 (44) |
| SBP levels <100 mm Hg | 188 (9.1) | 32 (7.8) |
| Heart rate >100 bpm | 727 (36) | 122 (30) |
| Sat O2 levels <90% | 298 (29) | 43 (24) |
| Isolated DVT | 1468 (42) | 514 (56) |
| Proximal | 1178 (80) | 320 (62) |
| Bilateral lower limb | 69 (4.7) | 25 (4.9) |
| Upper limb | 309 (21) | 198 (38) |
| Comorbidities, n (%) | ||
| Chronic heart disease | 185 (5.2) | 50 (5.4) |
| Chronic lung disease | 443 (13) | 99 (11) |
| Chronic liver disease | 100 (2.8) | 22 (2.4) |
| Atrial fibrillation | 115 (3.3) | 32 (3.5) |
| Recent (<30 days) major bleeding | 75 (2.1) | 13 (1.4) |
| Anemia | 1442 (41) | 351 (38) |
| Platelet count <100,000/mm3 | 174 (4.9) | 44 (4.8) |
| CrCl levels ˂30 mL/min | 142 (4.0) | 29 (3.1) |
| Additional risk factors for VTE | ||
| Postoperative | 486 (14%) | 117 (13%) |
| Recent immobility ≥4 days | 579 (16%) | 114 (12%) |
| Prior VTE | 266 (7.5%) | 89 (9.6%) |
| Concomitant medications, n (%) | ||
| Corticosteroids | 613 (19) | 135 (16) |
| Antiplatelets | 540 (16) | 113 (13) |
Abbreviations: bpm, beats per minute; CrCl, creatinine clearance; DVT, deep vein thrombosis; LMWH, low‐molecular‐weight heparin; PE, pulmonary embolism; SBP, systolic blood pressure; SD, standard deviation; VTE, venous thromboembolism.
a
Information on race/ethnicity was incorporated in RIETE on April 2014.